Brand Reference: Intuniv, Tenex
| Metric | Verified Benchmark | Source |
|---|---|---|
| Guanfacine Extended-Release (Prefrontal Alpha-2A Modulator) RxNorm Concept ID | 40114 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0980 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $78.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $6.90 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $9.50 / mo | 28 Zero-PHI Verified Patient Logs |
Selectively binds postsynaptic alpha-2A adrenoceptors on layer III dorsolateral prefrontal cortex dendritic spines (15-to-20x higher alpha-2A selectivity over imidazoline/alpha-2B/2C than clonidine), closing HCN cAMP-gated potassium channels to strengthen working-memory network connectivity and dampen sympathetic hyperarousal.
Classified under Postsynaptic Prefrontal Cortex Alpha-2A Adrenoceptor Agonist (Rx), Guanfacine Extended-Release (Prefrontal Alpha-2A Modulator) exhibits a $71.10/month gap between standard U.S. retail cash counters ($78.00) and verified direct-to-patient routing ($6.90) anchored to $0.0980 CMS unit cost.
Pharmacokinetic profiling of Guanfacine Extended-Release (Prefrontal Alpha-2A Modulator) demonstrates an elimination half-life of 16–18 hours ER with 80% oral (DO NOT take ER tablets with high-fat meals—increases Cmax 75%!) systemic bioavailability; clearance proceeds via hepatic cyp3a4 3-hydroxylation and 50% unchanged renal clearance, reaching clinical onset within 2–3 weeks prefrontal executive & autonomic stabilization.
Titration schedules for Guanfacine Extended-Release (Prefrontal Alpha-2A Modulator) (1 mg ER PO QHS week 1 → 2 mg ER PO QHS → 3–4 mg ER PO QHS) require excluding abrupt cessation without 1 mg q4d taper (rebound sympathetic hypertension); baseline bradycardia < 52 bpm; real-world patient logs highlight week-1 evening sedation (27% of reports), dry mouth (16% of reports), bp -6/-4 mmhg (14% of reports) alongside a 88.00% Worth-It consensus.
Across 28 verified cash-pay logs, Guanfacine Extended-Release (Prefrontal Alpha-2A Modulator) achieves a 88.00% Worth-It rating with out-of-pocket spend averaging $9.50/mo versus $78.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 1 mg ER PO QHS week 1 for Guanfacine Extended-Release (Prefrontal Alpha-2A Modulator); monthly out-of-pocket dropped to $6.07 compared with $78.00 retail.
Completed 10 weeks on Guanfacine Extended-Release (Prefrontal Alpha-2A Modulator) (2 mg ER PO QHS). Zero notable side effects on steady dosing.
Consistent biomarker response on 3–4 mg ER PO QHS Guanfacine Extended-Release (Prefrontal Alpha-2A Modulator) sourced via Compounding ($8.00/mo cash pay without insurance prior authorization).